Immix Biopharma (IMMX) Return on Capital Employed (2022 - 2026)
Immix Biopharma's (IMMX) quarterly Return on Capital Employed came in at 40.18% in Q1 2026, up 13953.0% year-on-year from N/an in Q1 2025, and up 29.78% quarter-over-quarter from 57.22% in Q4 2025.
Immix Biopharma (IMMX) Return on Capital Employed (2022 - 2026) Analysis & Trends
Immix Biopharma has disclosed Return on Capital Employed across 5 years of filings, most recently posting 40.18% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 40.18%, up 13953.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 40.18% (up 13953.0% YoY), and the FY2025 annual result was 55.7%, up 12215.0% from the prior year.
- Return on Capital Employed came in at 40.18% for Q1 2026 at Immix Biopharma, up from 57.22% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 13.44% in Q1 2022 to a low of 343.22% in Q3 2025.
- The 5-year median for Return on Capital Employed is 55.24% (2022), against an average of 93.99%.
- Across the five-year window, Return on Capital Employed sank 28823 bps in 2025 and soared 13953 bps in 2026, its largest moves.
- Immix Biopharma's Return on Capital Employed stood at 55.24% in 2022, then jumped by 55 bps to 24.65% in 2023, then plunged by 499 bps to 147.64% in 2024, then soared by 61 bps to 57.22% in 2025, then advanced by 30 bps to 40.18% in 2026.
- The last three Return on Capital Employed figures came in at 40.18% (Q1 2026), 57.22% (Q4 2025), and 343.22% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -107.40% |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -50.43% |
| 10 | Immix Biopharma | 467.59 Mn | 467.59 Mn | - | -40.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.18% |
| Dec 31, 2025 | -57.22% |
| Sep 30, 2025 | -343.22% |
| Jun 30, 2025 | -306.72% |
| Mar 31, 2025 | -179.71% |
| Dec 31, 2024 | -147.64% |
| Sep 30, 2024 | -54.99% |
| Jun 30, 2024 | -30.19% |
| Mar 31, 2024 | -34.35% |
| Dec 31, 2023 | -24.65% |
| Sep 30, 2023 | -89.90% |
| Jun 30, 2023 | -96.47% |
| Mar 31, 2023 | -74.76% |
| Dec 31, 2022 | -55.24% |
| Sep 30, 2022 | -28.55% |
| Jun 30, 2022 | -20.66% |
| Mar 31, 2022 | -13.44% |